Cancer Therapy
Data on Cancer Therapy Reported by G.K. Dy and Co-Researchers
Published in Drug Week, June 24th, 2011
2011 JUN 24 -- "There is abundant scientific evidence showing the key role of the insulin-like growth factor 1 receptor (ICE-I receptor, CD221) pathway in the malignant transformation of cells and in mediating resistance to various anticancer therapies. A rational approach in modulating this pathway is through blockade of growth factor signaling at the ligand-receptor interface," researchers in Buffalo, United States report.
"Dalotuzumab (MK-0646) is a recombinant humanized IgG(1) monoclonal antibody that binds specifically to CD221. It is currently in clinical development for the treatment of a wide variety of malignancies, such as cancers of the breast,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2011-06-24)
More Articles from Drug Week
- Cell Press
Apple ingredient keeps muscles strong - Cancer Therapy
Data from University of California Provide New Insights into Cancer Therapy - Parkinson's Disease
Data on Parkinson's Disease Described by H.S. Foyet et al - Nanoparticles
Findings from Bharati Vidyapeeth University Broaden Understanding of Nanoparticles - Developmental Neurobiology
Investigators at University of Michigan Have Published New Data on Developmental Neurobiology - Cancer Therapy
Investigators at University of Shandong Release New Data on Cancer Therapy - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
